Search

Displaying results 911 - 920 of 8468 in total
  1. Drug

    Phenylephrine

    go.drugbank.com/drugs/DB00388
    ApprovedInvestigational

    [A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]

    Mixtures: PAX FORTE, PAX FORTE®Categories: Sympathomimetics Used as Decongestants
  2. Drug

    Propiolactone

    go.drugbank.com/drugs/DB09348
    ApprovedWithdrawn

    It has been used against bacteria, fungi, and virus.[A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. … Propiolactone was first commercially available in the United States in 1958.[A32144]

  3. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    Rose bengal is a pink stain derived as an analogue of fluorescein. Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells. … The clinical applications of rose bengal as injectable formulation under the name PV-10 in melanoma, breast cancer and skin conditions such as eczema and psoriasis are being investigated in clinical trials

  4. Drug

    Levonorgestrel

    go.drugbank.com/drugs/DB00367
    ApprovedInvestigational

    [A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. … It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogenic adverse effects when compared

    Products: Her style, Her Style
  5. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

  6. Drug

    Somatrem

    go.drugbank.com/drugs/DB09098
    ApprovedWithdrawn

    Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent...

    Mixtures: Protropin Pws 5mg/vial, Protropin Inj Pws 10mg/vial
  7. Drug

    Guanfacine

    go.drugbank.com/drugs/DB01018
    ApprovedInvestigational

    [L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release

  8. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    As a liposomal formulation, mifamurtide demonstrates an enhanced tumoricidal effect and improved safety profile [A31745]. Mifamurtide is marketed in Europe as Mepact for intravenous infusion. … MDP is a motif present in all gram-positive and gram-negative bacterial walls that is recognized by different signalling molecules and activators such as nucleotide-binding and oligomerization domain (

  9. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

  10. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380] … [A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.

    Mixtures: PMS-dorzolamide-timolol